FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158144637> ?p ?o ?g. }

• W2158144637 endingPage "2148" @default.
• W2158144637 startingPage "2142" @default.
• W2158144637 abstract "To compare the pharmacokinetics/dynamics of the long-acting insulin analog glargine with NPH, ultralente, and continuous subcutaneous (SC) infusion of insulin lispro (continuous subcutaneous insulin infusion [CSII]), 20 C-peptide-negative type 1 diabetic patients were studied on four occasions during an isoglycemic 24-h clamp. Patients received SC injection of either 0.3 U/kg glargine or NPH insulin (random sequence, crossover design). On two subsequent occasions, they received either an SC injection of ultralente (0.3 U/kg) or CSII (0.3 U x kg(-1) x 24 h(-1)) (random sequence, crossover design). After SC insulin injection or CSII, intravenous (IV) insulin was tapered, and glucose was infused to clamp plasma glucose at 130 mg/dl for 24 h. Onset of action (defined as reduction of IV insulin &gt;50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P &lt; 0.05) (mean +/- SE). End of action (defined as an increase in plasma glucose &gt;150 mg/dl) occurred later with glargine (22 +/- 4 h) than with NPH (14 +/- 3 h) (P &lt; 0.05) but was similar with ultralente (20 +/- 6 h). NPH and ultralente exhibited a peak concentration and action (at 4.5 +/- 0.5 and 10.1 +/- 1 h, respectively) followed by waning, whereas glargine had no peak but had a flat concentration/action profile mimicking CSII. Interindividual variability (calculated as differences in SD of plasma insulin concentrations and glucose infusion rates in different treatments) was lower with glargine than with NPH and ultralente (P &lt; 0.05) but was similar with glargine and CSII (NS). In conclusion, NPH and ultralente are both peak insulins. Duration of action of ultralente is greater, but intersubject variability is also greater than that of NPH. Glargine is a peakless insulin, it lasts nearly 24 h, it has lower intersubject variability than NPH and ultralente, and it closely mimics CSII, the gold standard of basal insulin replacement." @default.
• W2158144637 created "2016-06-24" @default.
• W2158144637 creator A5003557683 @default.
• W2158144637 creator A5007297158 @default.
• W2158144637 creator A5010251404 @default.
• W2158144637 creator A5028060158 @default.
• W2158144637 creator A5030358562 @default.
• W2158144637 creator A5041675153 @default.
• W2158144637 creator A5051228228 @default.
• W2158144637 creator A5053050150 @default.
• W2158144637 creator A5057323309 @default.
• W2158144637 creator A5076593741 @default.
• W2158144637 date "2000-12-01" @default.
• W2158144637 modified "2023-10-11" @default.
• W2158144637 title "Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro." @default.
• W2158144637 cites W1988812448 @default.
• W2158144637 cites W1997676993 @default.
• W2158144637 cites W2008537144 @default.
• W2158144637 cites W2012130052 @default.
• W2158144637 cites W2013089541 @default.
• W2158144637 cites W2015818981 @default.
• W2158144637 cites W2021160326 @default.
• W2158144637 cites W2039265716 @default.
• W2158144637 cites W2042745397 @default.
• W2158144637 cites W2058777107 @default.
• W2158144637 cites W2064936958 @default.
• W2158144637 cites W2065544193 @default.
• W2158144637 cites W2074329116 @default.
• W2158144637 cites W2081528927 @default.
• W2158144637 cites W2085381118 @default.
• W2158144637 cites W2090413848 @default.
• W2158144637 cites W2105256076 @default.
• W2158144637 cites W2110177016 @default.
• W2158144637 cites W2138112294 @default.
• W2158144637 cites W2161306825 @default.
• W2158144637 cites W2168588540 @default.
• W2158144637 cites W2272801351 @default.
• W2158144637 cites W2322256252 @default.
• W2158144637 cites W2412339843 @default.
• W2158144637 cites W2513657840 @default.
• W2158144637 cites W2769264260 @default.
• W2158144637 cites W2316423620 @default.
• W2158144637 doi "https://doi.org/10.2337/diabetes.49.12.2142" @default.
• W2158144637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11118018" @default.
• W2158144637 hasPublicationYear "2000" @default.
• W2158144637 type Work @default.
• W2158144637 sameAs 2158144637 @default.
• W2158144637 citedByCount "779" @default.
• W2158144637 countsByYear W21581446372012 @default.
• W2158144637 countsByYear W21581446372013 @default.
• W2158144637 countsByYear W21581446372014 @default.
• W2158144637 countsByYear W21581446372015 @default.
• W2158144637 countsByYear W21581446372016 @default.
• W2158144637 countsByYear W21581446372017 @default.
• W2158144637 countsByYear W21581446372018 @default.
• W2158144637 countsByYear W21581446372019 @default.
• W2158144637 countsByYear W21581446372020 @default.
• W2158144637 countsByYear W21581446372021 @default.
• W2158144637 countsByYear W21581446372022 @default.
• W2158144637 countsByYear W21581446372023 @default.
• W2158144637 crossrefType "journal-article" @default.
• W2158144637 hasAuthorship W2158144637A5003557683 @default.
• W2158144637 hasAuthorship W2158144637A5007297158 @default.
• W2158144637 hasAuthorship W2158144637A5010251404 @default.
• W2158144637 hasAuthorship W2158144637A5028060158 @default.
• W2158144637 hasAuthorship W2158144637A5030358562 @default.
• W2158144637 hasAuthorship W2158144637A5041675153 @default.
• W2158144637 hasAuthorship W2158144637A5051228228 @default.
• W2158144637 hasAuthorship W2158144637A5053050150 @default.
• W2158144637 hasAuthorship W2158144637A5057323309 @default.
• W2158144637 hasAuthorship W2158144637A5076593741 @default.
• W2158144637 hasBestOaLocation W21581446371 @default.
• W2158144637 hasConcept C111113717 @default.
• W2158144637 hasConcept C112705442 @default.
• W2158144637 hasConcept C126322002 @default.
• W2158144637 hasConcept C134018914 @default.
• W2158144637 hasConcept C142724271 @default.
• W2158144637 hasConcept C204787440 @default.
• W2158144637 hasConcept C27081682 @default.
• W2158144637 hasConcept C2776390293 @default.
• W2158144637 hasConcept C2776486108 @default.
• W2158144637 hasConcept C2777391703 @default.
• W2158144637 hasConcept C2778804033 @default.
• W2158144637 hasConcept C2778808658 @default.
• W2158144637 hasConcept C2779306644 @default.
• W2158144637 hasConcept C2779920387 @default.
• W2158144637 hasConcept C2779946736 @default.
• W2158144637 hasConcept C2780352109 @default.
• W2158144637 hasConcept C2780668416 @default.
• W2158144637 hasConcept C46821324 @default.
• W2158144637 hasConcept C71924100 @default.
• W2158144637 hasConcept C87813604 @default.
• W2158144637 hasConceptScore W2158144637C111113717 @default.
• W2158144637 hasConceptScore W2158144637C112705442 @default.
• W2158144637 hasConceptScore W2158144637C126322002 @default.
• W2158144637 hasConceptScore W2158144637C134018914 @default.
• W2158144637 hasConceptScore W2158144637C142724271 @default.
• W2158144637 hasConceptScore W2158144637C204787440 @default.

• next